NEW YORK, Aug. 24, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, has agreed to work with Forian Inc. (NASDAQ: FORA), a leading provider of evidence-based support for more comprehensive clinical and commercial decision-making. MindMed and Forian will collaborate to develop best…

Source

Previous articleNavigating Psychedelics for Clinicians and Therapists – Q+A
Next articlePT259 – Dr. Devon Christie and Will Siu, MD, DPhil – The Mind-Body Connection, MDMA, and Chronic Pain